Tag: FGFR2

Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies

FGFR inhibitors have been developed to inhibit FGFR activation and signal transduction; notwithstanding, currently the selection of intrahepatic cholangiocarcinoma (iCCA) patients for these drugs only relies on the detection of FGFR2 genetic alterations (GAs) in tumor tissues or circulating tumor DNAs, without concomitant assessment of FGFR2 signalling status. Accordingly, we…

Continue Reading Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies

FDA Approves Erdafitinib for FGFR3+ Locally Advanced or Metastatic Urothelial Carcinoma

The FDA has approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 alterations, as determined by an FDA-approved test, whose disease has progressed on or following at least 1 prior line of systemic therapy. The agent is not recommended for those who are…

Continue Reading FDA Approves Erdafitinib for FGFR3+ Locally Advanced or Metastatic Urothelial Carcinoma

FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma With FGFR3 Mutations

FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma With FGFR3 Mutations The FDA has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic mutations whose disease has progressed on or after previously receiving one line of systemic…

Continue Reading FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma With FGFR3 Mutations

FDA Approves Balversa for Locally Advanced, Metastatic Urothelial Carcinoma

Image credit: Matthieu | stock.adobe.com The FDA has approved Balversa (erdafitinib) for adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic mutations whose disease progressed on or following one line of systemic therapy.1 The regulatory action amends the accelerated approval granted by the FDA in April 2019 for patients…

Continue Reading FDA Approves Balversa for Locally Advanced, Metastatic Urothelial Carcinoma

FDA grants full approval to erdafitinib for FGFR3-positive urothelial carcinoma

The FDA has granted a full approval to erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least 1 line of prior systemic therapy. It is not recommended for patients who,…

Continue Reading FDA grants full approval to erdafitinib for FGFR3-positive urothelial carcinoma

Ground News – Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

News Medical Center Mixed Factuality Other: Ian Birkby Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing…

Continue Reading Ground News – Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion

TOKYO, Dec 19, 2023 – (JCN Newswire) – Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, “tasurgratinib”) for biliary tract…

Continue Reading Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion

Eisai files biliary tract cancer drug tasurgratinib in Japan

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion mutations. The application to the Ministry of Health, Labour and Welfare (MHLW) is set for a priority review, reflecting the relatively high…

Continue Reading Eisai files biliary tract cancer drug tasurgratinib in Japan

An FGFR2 mutation as the potential cause of a new phenotype including early-onset osteoporosis and bone fractures: a case report | BMC Medical Genomics

Anamnesis vitae A 13 year old male born was as result of the VII pregnancy, from unrelated parents. Other pregnancies resulted in: I-II silent miscarriage in the second trimester; III – female, born in 2003 (III-3 Fig. 1) that has the following phenotypic features: genu valgum, hip dysplasia, combined thoracolumbar scoliosis,…

Continue Reading An FGFR2 mutation as the potential cause of a new phenotype including early-onset osteoporosis and bone fractures: a case report | BMC Medical Genomics

Formononetin | FGFR2 inhibitor | Axon 4067

All All Products Enzymes Receptors Ion Channels Research Areas Oxidoreductases Transferases Lyases Isomerases Ligases Nuclear Receptors Ligand-gated ATP-Sensitive Angiogenesis Apoptosis Cardiovascular Cell Cycle Regulation Cell Signaling & Oncology CNS Diabetes & Metabolism Epigenetics Immunology Miscellaneous Pain & Inflammation Stem Cell Oxidases MAO Cys-loop, cationic Cis-Trans Isomerase CypA DNA Topoisomerase Synthetases…

Continue Reading Formononetin | FGFR2 inhibitor | Axon 4067

Fibroblast Growth Factor Receptor 2 Inhibitor Market Focuses on Market Share, Size and Projected Forecast Till 2030 | by Isomjohnson | Dec, 2023

What is Fibroblast Growth Factor Receptor 2 Inhibitor? Fibroblast Growth Factor Receptor 2 (FGFR2) inhibitors have emerged as a promising therapeutic class in the field of precision medicine, particularly in the treatment of certain types of cancer. These inhibitors selectively target the FGFR2 signaling pathway, which is responsible for stimulating…

Continue Reading Fibroblast Growth Factor Receptor 2 Inhibitor Market Focuses on Market Share, Size and Projected Forecast Till 2030 | by Isomjohnson | Dec, 2023

Cholangiocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

PRESS RELEASE Published December 11, 2023 DelveInsight’s, “Cholangiocarcinoma Pipeline Insight 2023” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type,…

Continue Reading Cholangiocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

Cholangiocarcinoma Pipeline Drugs Analysis Report(2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

PRESS RELEASE Published December 12, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cholangiocarcinoma pipeline constitutes 55+ key companies continuously working towards developing 60+ Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Cholangiocarcinoma Pipeline report embraces…

Continue Reading Cholangiocarcinoma Pipeline Drugs Analysis Report(2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

FGFR2 point mutation in 2 cases of pleomorphic adenoma progressing to myoepithelial carcinoma

1. Carlson ER, Schlieve T. Salivary gland malignancies. Oral Maxillofac Surg Clin North Am 2019; 31: 125-144. 2. Seethala RR. Salivary gland tumors: current concepts and controversies. Surg Pathol Clin 2017; 10: 155-176. 3. Bradley PJ, McGurk M. Incidence of salivary gland neoplasms in a defined UK population….

Continue Reading FGFR2 point mutation in 2 cases of pleomorphic adenoma progressing to myoepithelial carcinoma

Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition

Patients, tumour Implantation, PDX expansion and characterization The study was conducted according to the Declaration of Helsinki. Tumours were collected from EC patients following Human Research Ethics Committee (HREC) approval (HREC/15/MHS/127) and QUT HREC (#1500000169, 1500000323). All participants provided written informed consent that their excess tissue could be used for…

Continue Reading Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition

20-OR | FGFR2 FISH Probe, Dye Color: Orange Biotrend

Gene Summary The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of…

Continue Reading 20-OR | FGFR2 FISH Probe, Dye Color: Orange Biotrend

Sympathetic Neurotransmitter, VIP, Delays Intervertebral Disc Degeneration via FGF18/FGFR2-Mediated Activation of Akt Signaling Pathway

Neuromodulation-related intervertebral disc degeneration (IVDD) is a novel IVDD pattern and are proposed recently. However, the mechanistic basis of neuromodulation and intervertebral disc (IVD) homeostasis remains unclear. Here, this study aimed to investigate the expression of postganglionic sympathetic nerve fiber-derived vasoactive intestinal peptide (VIP) system in human IVD tissue, and…

Continue Reading Sympathetic Neurotransmitter, VIP, Delays Intervertebral Disc Degeneration via FGF18/FGFR2-Mediated Activation of Akt Signaling Pathway

Decoding Fibroblast Growth Factor Receptor 2 Market Metrics: Market Share, Trends, and Growth Patterns | by Tammyfreeman | Dec, 2023

Market Overview and Report Coverage Fibroblast Growth Factor Receptor 2 (FGFR2) is a protein found on the surface of cells that plays a crucial role in cell growth, division, and differentiation. It is a receptor for fibroblast growth factors (FGFs), which are a group of proteins responsible for controlling various…

Continue Reading Decoding Fibroblast Growth Factor Receptor 2 Market Metrics: Market Share, Trends, and Growth Patterns | by Tammyfreeman | Dec, 2023

Influence of FGF4 and BMP4 on FGFR2 dynamics during the segregation of epiblast and primitive endoderm cells in the pre-implantation mouse embryo

Fig 4. Treatment of FGFR2-eGFP embryos with FGF4 or ERK inhibitor. A) Representative images of live imaged FGFR2-eGFP embryos at different embryonic days and consequently different exposure to treatment. Scale bar is equal to 47μm. B) Representative images of embryos immunostained for NANOG (grey) and GATA6 (red) at different embryonic…

Continue Reading Influence of FGF4 and BMP4 on FGFR2 dynamics during the segregation of epiblast and primitive endoderm cells in the pre-implantation mouse embryo

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two poster presentations at the upcoming 2023 San Antonio Breast Cancer Symposium (SABCS), taking place December 5-9, 2023 at the Henry…

Continue Reading Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

KEGG T01007: 415125

Entry 415125            CDS       T01007                                  Symbol FGFR2 Name (RefSeq) fibroblast growth factor receptor 2 precursor   KO K05093   fibroblast growth factor receptor 2 [EC:2.7.10.1] Organism cfa  Canis lupus familiaris (dog) Pathway cfa01521   EGFR tyrosine kinase inhibitor resistance cfa04010   MAPK signaling pathway cfa04014   Ras signaling pathway cfa04015   Rap1 signaling pathway cfa04020   Calcium signaling pathway cfa04144   Endocytosis…

Continue Reading KEGG T01007: 415125

ESRP1 controls biogenesis and function of a large abundant multiexon circRNA | Nucleic Acids Research

Abstract While the majority of circRNAs are formed from infrequent back-splicing of exons from protein coding genes, some can be produced at quite high level and in a regulated manner. We describe the regulation, biogenesis and function of circDOCK1(2–27), a large, abundant circular RNA that is highly regulated during epithelial-mesenchymal…

Continue Reading ESRP1 controls biogenesis and function of a large abundant multiexon circRNA | Nucleic Acids Research

CIMP Gives The Green Light To Three New Orphan Drugs For Rare Diseases

The Interministerial Commission on Drug Prices (CIPM) proposed at its last meeting in November the total or partial financing of 8 new drugs (three of which are orphan drugs for rare diseases) and 3 new indications for 2 additional drugs, already authorized and previously funded. in other signs. The new…

Continue Reading CIMP Gives The Green Light To Three New Orphan Drugs For Rare Diseases

Shen, Chen-Yang – IBMS, Sinica

FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis. Dr. Shen, Chen-Yang Hum Mol Genet., May 18, 2015 The association between breast cancer risk and genetic variants of fibroblast growth factor receptor 2 (FGFR2) has been identified and repeatedly confirmed;…

Continue Reading Shen, Chen-Yang – IBMS, Sinica

Stand Up To Cancer announces three teams focu

image:  Stand Up To Cancer Logo view more  Credit: Stand Up To Cancer LOS ANGELES – Nov. 15, 2023 – Stand Up To Cancer® (SU2C) today announced three Research Teams focused on bringing new therapies to clinical trials for the treatment of gastroesophageal cancer (GEC). The Research Teams, a part…

Continue Reading Stand Up To Cancer announces three teams focu

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas | Cell & Bioscience

Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology. 2009;136(4):1134–44. Article  PubMed  Google Scholar  Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14. Article  PubMed  Google Scholar  Nakanuma Y, Klimstra DS, Komuta M, Zen Y (2019) Intrahepatic…

Continue Reading Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas | Cell & Bioscience

Dr Baretti on the Mechanisms of Resistance Associated With FGFR2+ Cholangiocarcinoma

Marina Baretti, MD, assistant professor, oncology, Johns Hopkins Medicine, discusses innate and acquired mechanisms of resistance in patients with unresectable, advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements. Although previous data have demonstrated the efficacy of approved FGFR-targeted agents, such as pemigatinib (Pemazyre) and infigratinib (Truseltiq), in…

Continue Reading Dr Baretti on the Mechanisms of Resistance Associated With FGFR2+ Cholangiocarcinoma

Relay: Market Underestimating Lirafugratinib’s Potential (Upgrade) (RLAY)

Anchiy At a Glance Relay Therapeutics (NASDAQ:RLAY) has reached a critical phase, juxtaposing strong financial foundations against increasing operational costs, which I have previously analyzed in depth. Since my last evaluation, lirafugratinib’s clinical momentum has been maintained in the Phase 1/2 ReFocus trial, showing significant promise for FGFR2-altered cholangiocarcinoma, although…

Continue Reading Relay: Market Underestimating Lirafugratinib’s Potential (Upgrade) (RLAY)

Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights

Relay Therapeutics, Inc. Reported initial RLY-4008 (lirafugratinib) data demonstrating durable responses across multiple FGFR2-altered solid tumors Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinations in HR+/HER2- breast cancer by YE 2023 Updated pipeline to extend cash runway by approximately 1 year Approximately $811 million in cash, cash…

Continue Reading Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights

Dr Baretti on the Utility of FGFR Inhibitors in FGFR2+ Intrahepatic Cholangiocarcinoma

Marina Baretti, MD, assistant professor, oncology, Johns Hopkins University, Johns Hopkins Hospital, discusses the evolving utility of FGFR inhibitors in the treatment of patients with unresectable, advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. The oncology field has made notable progress in transitioning molecularly targeted therapies…

Continue Reading Dr Baretti on the Utility of FGFR Inhibitors in FGFR2+ Intrahepatic Cholangiocarcinoma

A Deep Dive into the Latest Market Trends, Market Segmentation, and Competitive Ana

Fibroblast Growth Factor Receptor 2 Inhibitor Market Analysis and Latest Trends Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitors are drugs that work by inhibiting the activity of the FGFR2 receptor, which plays a crucial role in cell growth, differentiation, and embryonic development. These inhibitors are primarily used in the treatment…

Continue Reading A Deep Dive into the Latest Market Trends, Market Segmentation, and Competitive Ana

NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology

Patient characteristics and tissue context The clinical interpretation of molecular alterations starts with evaluating relevant patient characteristics and the tissue context in which a genetic profile occurs. The former relates, in particular, to previous therapies, in addition to disease stage and clinical performance status. For example, prior targeted therapies warrant…

Continue Reading NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

LianBio SHANGHAI, China and PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) —  LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the presentation of efficacy and safety data from a Phase 2a study evaluating infigratinib in Chinese patients…

Continue Reading LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

List of variants in gene FGFR2 studied for female reproductive system neoplasm

Minimum submission review status: ★☆☆☆ criteria provided ★★★☆ reviewed by expert panel ★★★★ practice guideline Collection method: clinical testing curation literature only research other Minimum conflict level: multiple submissions, potential for conflict synonymous conflict (e.g. benign vs non-pathogenic) confidence conflict (e.g. benign vs likely benign) benign or likely benign vs…

Continue Reading List of variants in gene FGFR2 studied for female reproductive system neoplasm

What new research is being done in bile duct cancer treatment?

For patients with cholangiocarcinoma, or bile duct cancer, the first line of treatment often includes standard cancer treatments, such as surgery, chemotherapy and radiation therapy. However, in the last few years, oncologists have found that there may be a better option for patients whose cancer has a mutation in the…

Continue Reading What new research is being done in bile duct cancer treatment?

MD Anderson research highlights: ESMO 2023 sp

ABSTRACTS: LBA71, 1088MO, 95MO, LBA48, 1082O, 1085O, LBA34, 243MO MADRID ― The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology…

Continue Reading MD Anderson research highlights: ESMO 2023 sp

The Next-Generation Broad-Spectrum Cancer Drug: RLY-4008

The Next-Generation Broad-Spectrum Cancer Drug: RLY-4008   The Next-Generation Broad-Spectrum Cancer Drug: RLY-4008, Shows Promising Data in Combatting Multiple Solid Tumor Cancers! Summary: Recently, a report from the 2023 AACR-NCI-EORTC Molecular Targeted and Cancer Treatment International Conference revealed that the new generation FGFR2 inhibitor, RLY-4008, demonstrated excellent efficacy in various…

Continue Reading The Next-Generation Broad-Spectrum Cancer Drug: RLY-4008

Positive Breast Cancer Data from Relay Therapeutics

Last week, Relay Therapeutics shared results about their experimental drug, RLY-4008, designed to treat a specific type of breast cancer. The drug is being tested in a two-step study named the “ReFocus trial.” They’ve completed the first step, and now they’re in the second step, figuring out the right dosage….

Continue Reading Positive Breast Cancer Data from Relay Therapeutics

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma | Clinical Cancer Research

Purpose: FGFR inhibitors are effective in FGFR2-altered cholangiocarcinoma, leading to approval of reversible FGFR inhibitors—pemigatinib and infigratinib—and an irreversible inhibitor—futibatinib. However, acquired resistance develops, limiting clinical benefit. Some mechanisms of resistance have been reported, including secondary FGFR kinase domain mutations. Here, we sought to establish the landscape of acquired resistance…

Continue Reading Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma | Clinical Cancer Research

Knight Therapeutics Announces CMED Price Approval of

MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). As a result, Knight expects to launch Minjuvi®…

Continue Reading Knight Therapeutics Announces CMED Price Approval of

Recombinant human FGFR2 (mutated E565G) protein (Active) (ab268565)

Recombinant human FGFR2 (mutated E565G) protein (Active) is a Baculovirus infected Sf9 Fragment protein 285 to 821 aa range, >75% purity and validated in SDS-PAGE, FuncS. Purity >75% Expression system Baculovirus infected Sf9 cells Tags GST tag N-Terminus Application SDS-PAGE, FuncS Biologically active Yes Reactivity data Application SDS-PAGE Reactivity Reacts…

Continue Reading Recombinant human FGFR2 (mutated E565G) protein (Active) (ab268565)

Cogent Biosciences Presents Preclinical Data Highlighting

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – – IND and initiation of clinical trial planned in 2H 2024 – WALTHAM, Mass. and BOULDER, Colo., Oct. 14, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq:…

Continue Reading Cogent Biosciences Presents Preclinical Data Highlighting

Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors

Lirafugratinib (RLY-4008) demonstrated clinical activity in multiple subsets of patients with FGFR2-altered solid tumors, including those with FGFR2-altered hormone receptor–positive, HER2-negative breast cancer, according to data from the phase 1/2 ReFocus trial (NCT04526106) presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.1,2 Efficacy with the agent…

Continue Reading Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors

Relay’s rare cancer drug delayed by IRA

Relay Therapeutics is altering its strategic course, driven by the effects of the Inflation Reduction Act (IRA), leading the biotech to pause its plans to bring the cancer drug lirafugratinib to market for a rare cancer. Instead, Relay has chosen to pursue a broader, tumor-agnostic opportunity. The Boston-based company initially…

Continue Reading Relay’s rare cancer drug delayed by IRA

Relay Therapeutics Pauses Lirafugratinib Rare Cancer Plans Due to IRA

Pictured: Finger pressing pause button/iStock, cagkansayin Relay Therapeutics announced plans Thursday to shift gears, pausing its push for rare cancer and switching focus to the larger tumor-agnostic market. The Boston-based biotech is pointing to the Inflation Reduction Act as a driving factor of its decision.  Relay’s FGFR2 inhibitor has been…

Continue Reading Relay Therapeutics Pauses Lirafugratinib Rare Cancer Plans Due to IRA

Relay Therapeutics Announces Initial RLY-4008

35% ORR in patients with FGFR2 fusions (excluding CCA) & 40% ORR in patients with FGFR2-altered HR+/HER2- breast cancer RLY-4008 commercialization plans to focus on broader tumor agnostic opportunities Clinical focus on PI3Kα mutant selective programs, with plans to initiate RLY-2608 triplet combinations in HR+/HER2- breast cancer by YE 2023…

Continue Reading Relay Therapeutics Announces Initial RLY-4008

Relay Therapeutics, Inc. Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors -October 12, 2023 at 04:05 pm EDT

Relay Therapeutics, Inc. announced initial clinical data for RLY-4008 (lirafugratinib) in patients with FGFR2-altered solid tumors. The first part of the study (dose escalation) is complete, and the second part of the study (dose expansion) is ongoing at the 70mg QD recommended Phase 2 dose. Most treatment-related adverse events were…

Continue Reading Relay Therapeutics, Inc. Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors -October 12, 2023 at 04:05 pm EDT

FGFR2 genetic variants in women with breast cancer

Spandidos Publications style Dix‑Peek T, Dickens C, Augustine TN, Phakathi BP, Van Den Berg EJ, Joffe M, Ayeni OA, Cubasch H, Nietz S, Mathew CG, Mathew CG, et al: FGFR2 genetic variants in women with breast cancer. Mol Med Rep 28: 226, 2023 APA Dix‑Peek, T., Dickens, C., Augustine, T.N.,…

Continue Reading FGFR2 genetic variants in women with breast cancer

Knight Therapeutics Announces Regulatory Submission of

MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for…

Continue Reading Knight Therapeutics Announces Regulatory Submission of

Recombinant Mouse Fgfr2 Protein, Myc/DDK-tagged Fgfr2-3002M

Description : Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis…

Continue Reading Recombinant Mouse Fgfr2 Protein, Myc/DDK-tagged Fgfr2-3002M

Computational mouse atlases and their application to automatic assessment of craniofacial dysmorphology caused by the Crouzon mutation fgfr2(c342y)

@article{b7d3a2aabdd04c358e702fa948e8688b, title = “Computational mouse atlases and their application to automatic assessment of craniofacial dysmorphology caused by the Crouzon mutation fgfr2(c342y)”, author = “Hildur Olafsdottir and Darvann, {Tron A.} and Hermann, {Nuno V.} and Estanislao Oubel and Ersboll, {Bjarne K.} and Frangi, {Alejandro F.} and Per Larsen and Perlyn, {Chad…

Continue Reading Computational mouse atlases and their application to automatic assessment of craniofacial dysmorphology caused by the Crouzon mutation fgfr2(c342y)

Relay Therapeutics Receives Moderate Buy Rating and Reports Q2 Earnings Shortfall

As of September 24, 2023, Relay Therapeutics, Inc. (NASDAQ:RLAY) has received an average rating of “Moderate Buy” from ten analysts covering the company, according to Bloomberg Ratings. Out of the ten analysts, two have recommended holding the stock, seven have advised buying it, and one has issued a strong buy…

Continue Reading Relay Therapeutics Receives Moderate Buy Rating and Reports Q2 Earnings Shortfall

Fibroblast Growth Factor Receptor 2 (FGFR2), a New Gene Involved in the Genesis of Autism Spectrum Disorder

The ASD patient described here showed a mutation in the FGFR2 gene, located in the chromosomal band 10q26 (Fig. 1a) and encoding the fibroblast growth factor receptor type 2. It belongs to the family of tyrosine kinase receptors (including FGFR1, FGFR3, and FGFR4) that regulate several biological processes, including bone development,…

Continue Reading Fibroblast Growth Factor Receptor 2 (FGFR2), a New Gene Involved in the Genesis of Autism Spectrum Disorder

Harbor Capital Advisors Inc. Acquires Stake in Relay Therapeutics, Inc.: A Promising Future in Precision Medicine

On September 20, 2023, it was reported that Harbor Capital Advisors Inc. had acquired a new stake in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during the second quarter. According to their Form 13F filing with the Securities & Exchange Commission, the institutional investor purchased 40,278 shares of the company’s…

Continue Reading Harbor Capital Advisors Inc. Acquires Stake in Relay Therapeutics, Inc.: A Promising Future in Precision Medicine

Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype

Background and aims: Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer for which effective therapeutic agents are lacking. Fibroblast growth factor receptor 2 (FGFR2) has become a promising therapeutic target in ICC; however, its incidence and optimum testing method have not been fully assessed. This study investigated the…

Continue Reading Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype

Relay Therapeutics to Unveil Groundbreaking Clinical Data on RLY4008 at AACRNCIEORTC International Conference

On September 18, 2023, Relay Therapeutics is set to unveil groundbreaking clinical data on their latest drug, RLY-4008, specifically designed to combat advanced FGFR2-altered solid tumors. The highly anticipated presentation will take place at the prestigious 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This conference serves as…

Continue Reading Relay Therapeutics to Unveil Groundbreaking Clinical Data on RLY4008 at AACRNCIEORTC International Conference

Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment

Patient characteristics In our analysis, we included patients with biliary tract cancer and available comprehensive molecular characterization data from five Austrian cancer centers. The data cut-off date was September 2022 (Fig. 1). Figure 1 Trial design: Flow chart depicting patient allocation. In total, the molecular profile of 159 patients with biliary…

Continue Reading Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment

Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Relay Therapeutics, Inc. CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that data for RLY-4008 (lirafugratinib) in patients with advanced FGFR2-altered solid tumors outside of cholangiocarcinoma…

Continue Reading Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Precision treatment of cholangiocarcinoma: current strategies and future directions

Cholangiocarcinoma is an aggressive malignant tumor originating from the biliary tract and can be divided into three subtypes based on anatomical location: intrahepatic cholangiocarcinoma, perihepatic cholangiocarcinoma, and distal cholangiocarcinoma [1]. Although progress has been made in the field of cholangiocarcinoma treatment in recent years, cholangiocarcinoma mortality remains high [2]. Although…

Continue Reading Precision treatment of cholangiocarcinoma: current strategies and future directions

FGFR2 Polyclonal Antibody Cy5 Conjugated

FGFR2 Polyclonal Antibody Cy5 Conjugated | ARP American Research Products, Inc. The store will not work correctly when cookies are disabled. JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser. More Information Product Name FGFR2…

Continue Reading FGFR2 Polyclonal Antibody Cy5 Conjugated

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma (HCC) or hepatocholangiocarcinoma (H-CCK) following disease progression on frontline atezolizumab (Tecentriq) and bevacizumab (Avastin) to targeted therapy or another TKI based on identified genomic alterations, according to retrospective findings from a single-center study presented at the 2023…

Continue Reading DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

ArrowMark Colorado Holdings Reduces Stake in Relay Therapeutics as Financial Challenges Persist

On September 12, 2023, it was reported that ArrowMark Colorado Holdings LLC has reduced its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 0.6% during the first quarter. According to the disclosure filed with the Securities & Exchange Commission, the institutional investor now owns approximately 2,670,197 shares of Relay…

Continue Reading ArrowMark Colorado Holdings Reduces Stake in Relay Therapeutics as Financial Challenges Persist

Fibroblast Growth Factor Receptor 2 market research report has seen immense growth at an exponential CAGR rate of 7% from 2023 to 2030 and provides in-depth analysis of Fibroblast Growth Factor Receptor 2 market.

The “Fibroblast Growth Factor Receptor 2 Market” is focused on controlling cost, and improving efficiency. Moreover, the reports offer both the demand and supply aspects of the market. The Fibroblast Growth Factor Receptor 2 market is expected to grow annually by 7% (CAGR 2023 – 2030). Fibroblast Growth Factor Receptor…

Continue Reading Fibroblast Growth Factor Receptor 2 market research report has seen immense growth at an exponential CAGR rate of 7% from 2023 to 2030 and provides in-depth analysis of Fibroblast Growth Factor Receptor 2 market.

Recombinant Human FGFR2 protein(IIIb), His-Avi-tagged FGFR2-055H

Description : Four distinct genes encoding closely related FGF receptors, FGF R1 – 4, are known. All four genes for FGF Rs encode proteins with an N-terminal signal peptide, three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII…

Continue Reading Recombinant Human FGFR2 protein(IIIb), His-Avi-tagged FGFR2-055H

Acutis Biosciences’ CSO Dr. Abdel Halim Co-Authors a Precision Medicine Study in NEJM

Highlights the value of companion diagnostics in the drug industry and the effectiveness of ctDNA testing in blood samples instead of invasive tumor biopsies for patient screening in clinical trials, The assay demonstrated ctDNA liquid biopsy can be an alternative or complement to tissue samples and decrease sample failure rate, Laboratory…

Continue Reading Acutis Biosciences’ CSO Dr. Abdel Halim Co-Authors a Precision Medicine Study in NEJM

Swiss National Bank Reduces Holdings in Relay Therapeutics as Company Faces Decreasing Profitability and Performance

In the first quarter of 2023, Swiss National Bank made a significant move by reducing its holdings in Relay Therapeutics, Inc. The bank trimmed its stake in the company by 10.1%, selling 19,000 shares during the quarter. After this transaction, Swiss National Bank owned approximately 169,700 shares of Relay Therapeutics,…

Continue Reading Swiss National Bank Reduces Holdings in Relay Therapeutics as Company Faces Decreasing Profitability and Performance

FGFR2 signaling in normal and limbless chick limb buds

文献主旨 Xu X, et al. 1998. Development125:753–765]. To explore thismodel, we have examined FGFR2b and FGFR2c mRNA expres- sion, using isoform-specific probes during the early stages of development of the chick limb when limb initiation, AER induction, and outgrowth are occurring. We have found that FGFR2b is expressed by limb…

Continue Reading FGFR2 signaling in normal and limbless chick limb buds

TimeTalk uses single-cell RNA-seq datasets to decipher cell-cell communication during early embryo development

Curation of early-embryo development single-cell RNA-seq data sets for studying cell-cell communication To identify and study eLRs, we collected public early embryo development scRNA-seq datasets from the mouse MII-oocyte stage to the late blastocyst stage to ensure that scRNA-seq datasets represented every stage of early embryo development. In addition, to…

Continue Reading TimeTalk uses single-cell RNA-seq datasets to decipher cell-cell communication during early embryo development

RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

The first highly selective FGFR2 inhibitor RLY-4008 has displayed preliminary efficacy in patients with cholangiocarcinoma and has the potential to establish another agent in the treatment paradigm, according to Mitesh J. Borad, MD. Borad presented updated results from the phase 1/2 ReFocus trial (NCT04526106) with the agent at the 2023…

Continue Reading RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

Cholangiocarcinoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

PRESS RELEASE Published August 31, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cholangiocarcinoma pipeline constitutes 55+ key companies continuously working towards developing 60+ Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Cholangiocarcinoma Pipeline report embraces…

Continue Reading Cholangiocarcinoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

Relay Therapeutics Receives Moderate Buy Rating and Shows Potential for Stock Growth

Relay Therapeutics, Inc. (NASDAQ:RLAY) has received a “Moderate Buy” rating from ten brokerages, according to Bloomberg Ratings. The company’s stock has garnered two hold recommendations, seven buy recommendations, and one strong buy recommendation from analysts. Brokerages that have issued reports on the stock in the past year have provided an…

Continue Reading Relay Therapeutics Receives Moderate Buy Rating and Shows Potential for Stock Growth

Dr. Zhang on the THOR trial of erdafitinib in urothelial carcinoma

In this video, Tian Zhang, MD, associate professor of Medicine at UT Southwestern Medical Center, discusses the phase 3 THOR trial (NCT03390504), which showed that erdafitinib significantly improved overall survival compared with investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who had previously received an anti–PD-(L)1 therapy.1,2…

Continue Reading Dr. Zhang on the THOR trial of erdafitinib in urothelial carcinoma

Janssen Seeks Approval for Balversa to Patients With Bladder Cancer

A supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration for the approval of Balversa (erdafitinib) to treat patients with locally advanced or metastatic urothelial carcinoma with FGFR3 or FGFR2 gene alterations, and progressed on a prior checkpoint inhibitor or within 12 months of…

Continue Reading Janssen Seeks Approval for Balversa to Patients With Bladder Cancer

Treatment Sequencing in Refractory Urothelial Carcinoma Requires a Personalized Approach

With the continued addition of new agents and an increased understanding of disease biology, the sequencing of treatments for patients with relapsed/refractory urothelial carcinoma requires an individualized approach, according to Jue Wang, MD. “Based on our understanding of refractory urothelial carcinoma, a trial-and-error approach doesn’t work. Several factors can guide…

Continue Reading Treatment Sequencing in Refractory Urothelial Carcinoma Requires a Personalized Approach

J&J (JNJ) Seeks Full FDA Nod for Balversa in Urothelial Cancer

Johnson & Johnson JNJ announced that it has submitted a supplemental new drug application (sNDA) to the FDA seeking full approval for Balversa (erdafitinib) as a treatment for patients with metastatic or unresectable urothelial carcinoma (UC), a type of bladder cancer. Balversa, a kinase inhibitor, was approved by the FDA under…

Continue Reading J&J (JNJ) Seeks Full FDA Nod for Balversa in Urothelial Cancer

Full FDA approval sought for erdafitinib for urothelial carcinoma

A supplemental New Drug Application (sNDA) has been filed with the FDA for the full approval of erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma harboring a susceptible FGFR3 alteration and disease progression after ≥1 PD-1/PD-L1 inhibitor in the locally advanced or metastatic…

Continue Reading Full FDA approval sought for erdafitinib for urothelial carcinoma

Janssen Seeks Full Approval for Erdafitinib in Metastatic Bladder CA

Janssen has submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) seeking full approval of erdafitinib (Balversa) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC), that has susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, and progressed during or following…

Continue Reading Janssen Seeks Full Approval for Erdafitinib in Metastatic Bladder CA

Janssen Seeks Full Approval for Balversa in FGFR3-Altered Bladder Cancer

NEW YORK – Janssen said on Monday that it is seeking full approval in the US for Balversa (erdafitinib) as a treatment for patients with FGFR3-altered locally advanced or metastatic urothelial carcinoma after progressing on an anti-PD-1/PD-L1 therapy in the metastatic setting or within a year of neoadjuvant or adjuvant…

Continue Reading Janssen Seeks Full Approval for Balversa in FGFR3-Altered Bladder Cancer

Industrial Alliance Investment Management Inc. Acquires Stake in Precision Medicines Company, Relay Therapeutics Inc.

On August 26, 2023, Industrial Alliance Investment Management Inc. revealed that it had acquired a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) during the first quarter. According to the filing submitted to the Securities & Exchange Commission, the fund purchased 110,590 shares of Relay Therapeutics’ stock with an estimated value…

Continue Reading Industrial Alliance Investment Management Inc. Acquires Stake in Precision Medicines Company, Relay Therapeutics Inc.

Dr Petrylak on Sequencing Questions in FGFR2/3-Altered Metastatic Urothelial Cancer

Daniel P. Petrylak, MD, professor, medicine, Medical Oncology and Urology, chief, Genitourinary Oncology, Yale School of Medicine, discusses sequencing treatment selections in patients with FGFR2/3-altered metastatic urothelial cancer. The optimal treatment sequencing for patients following a diagnosis of FGFR2/3-altered metastatic urothelial cancer remains unclear, Petrylak beings. Sequencing issues will arise…

Continue Reading Dr Petrylak on Sequencing Questions in FGFR2/3-Altered Metastatic Urothelial Cancer

Sci-Hub | High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathology – Research and Practice, 152878

Sci-Hub | High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathology – Research and Practice, 152878 | 10.1016/j.prp.2020.152878 ◂ ↓ save Hur, J. Y., Chao, J., Kim, K., Kim, S. T., Kim, K.-M., Klempner, S. J., & Lee, J. (2020). High-level FGFR2…

Continue Reading Sci-Hub | High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathology – Research and Practice, 152878

Human FGFR2 Alexa Fluor 350-conjugated Antibody, R D Systems 100ug; Alexa

Gene Alias BBDS, BEK, BFR-1, CD332, CD332 antigen, CEK3, CFD1, craniofacial dysostosis 1, EC 2.7.10, EC 2.7.10.1, ECT1, FGF R2, fibroblast growth factor receptor 2, FLJ98662, Jackson-Weiss syndrome, JWS, Keratinocyte growth factor receptorreceptor like 14, KGFR, K-sam, KSAM, soluble FGFR4 variant 4, TK14, TK25 Test Specificity Detects alpha isoforms (3…

Continue Reading Human FGFR2 Alexa Fluor 350-conjugated Antibody, R D Systems 100ug; Alexa

Relay Therapeutics: Revolutionizing Precision Medicines with Innovative Approaches and Promising Pipeline

Relay Therapeutics, Inc. is a clinical-stage precision medicines company that is revolutionizing the drug discovery process. With an initial focus on targeted oncology and genetic disease indications, Relay Therapeutics is using innovative approaches to enhance small molecule therapeutic discovery. Several research analysts have recently commented on the company’s prospects. Oppenheimer…

Continue Reading Relay Therapeutics: Revolutionizing Precision Medicines with Innovative Approaches and Promising Pipeline

Capula Management Ltd Acquires New Position in Relay Therapeutics, Inc. Despite Revenue Decline, Company Advances in Precision Medicine

Capula Management Ltd, a leading investment management firm, has recently acquired a new position in Relay Therapeutics, Inc. (NASDAQ: RLAY). According to the company’s recent Form 13F filing with the Securities & Exchange Commission, Capula Management Ltd purchased 30,380 shares of Relay Therapeutics’ stock during the 1st quarter, which amounts…

Continue Reading Capula Management Ltd Acquires New Position in Relay Therapeutics, Inc. Despite Revenue Decline, Company Advances in Precision Medicine

Biliary Tract Cancers Clinical Practice Guidelines (NCCN, 2023)

Recent updates to the National Comprehensive Cancer Network (NCCN) guidelines for the evaluation and management of patients with biliary tract cancers (BTCs) (gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma) were published in July 2023 in the Journal of the NCCN (JNCCN).[1] Select recommendations for molecular testing and for systemic therapy…

Continue Reading Biliary Tract Cancers Clinical Practice Guidelines (NCCN, 2023)

Barclays PLC Cuts Stake in Relay Therapeutics, Raises Questions about Investment Strategy

In a surprising move, Barclays PLC has slashed its stake in Relay Therapeutics, Inc. by 28.5% in the first quarter of this year. The decision was documented in the company’s latest filing with the Securities and Exchange Commission, revealing that Barclays now owns 194,470 shares of Relay Therapeutics’ stock after…

Continue Reading Barclays PLC Cuts Stake in Relay Therapeutics, Raises Questions about Investment Strategy

Analyzing Relay Therapeutics’ Q2 Earnings: Challenges and Potential Opportunities

August 14, 2023 &Check Out Our Latest Analysis on Relay Therapeutics Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicines company, recently reported its quarterly earnings results for the period ending on August 8th. The company’s performance has attracted attention due to some notable figures. In the second quarter, Relay Therapeutics announced…

Continue Reading Analyzing Relay Therapeutics’ Q2 Earnings: Challenges and Potential Opportunities

Pfeiffer syndrome: clinical and genetic findings in five Brazilian families.

@article{Jnior2015PfeifferSC, title={Pfeiffer syndrome: clinical and genetic findings in five Brazilian families.}, author={Herc{\’i}lio Martelli J{\’u}nior and Sibele Nascimento de Aquino and Renato Assis Machado and Let{\’i}cia Lima Le{\~a}o and Ricardo Della Coletta and Marcos-Jos{\’e} Burle-Aguiar}, journal={Medicina oral, patologia oral y cirugia bucal}, year={2015}, volume={20 1}, pages={ e52-8 }, url={https://api.semanticscholar.org/CorpusID:7413806} } The…

Continue Reading Pfeiffer syndrome: clinical and genetic findings in five Brazilian families.

What is the current valuation of Relay Therapeutics’s Lirafugratinib Hydrochloride

The revenue for Lirafugratinib Hydrochloride is expected to reach an annual total of $27 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net…

Continue Reading What is the current valuation of Relay Therapeutics’s Lirafugratinib Hydrochloride

Promising Outlook for Precision Medicines Pioneer: Relay Therapeutics Reports Q2 Earnings

Relay Therapeutics (NASDAQ:RLAY), a leading precision medicines company, recently released its latest earnings report on August 8th, 2023. The report revealed key insights into the company’s financial performance and progress in its mission to revolutionize drug discovery. In the second quarter, Relay Therapeutics reported an earnings per share (EPS) of…

Continue Reading Promising Outlook for Precision Medicines Pioneer: Relay Therapeutics Reports Q2 Earnings

Leerink Partners Reaffirms Outperform Rating for Relay Therapeutics with Projections of Earnings and Market Performance

In a recent research note issued on August 10, 2023, by Leerink Partners, Relay Therapeutics (NASDAQ:RLAY) received an “outperform” rating reaffirmation. Alongside this rating, the renowned equities research analysts from Leerink Partners released various estimates for the company’s earnings throughout the year and into FY2027. Leerink Partners presented their projections…

Continue Reading Leerink Partners Reaffirms Outperform Rating for Relay Therapeutics with Projections of Earnings and Market Performance

Taraxasterol suppresses the proliferation and tumor growth of androgen-independent prostate cancer cells through the FGFR2-PI3K/AKT signaling pathway

All experimental protocols were approved by Dali University. All methods were performed in accordance with relevant guidelines and regulations. Reagents and chemicals MEM medium, RPMI-1640 medium, fetal bovine serum (FBS), phosphate-buffered saline (PBS), and penicillin–streptomycin (Pen Strep) were purchased from Biological Industries (Israel). CCK-8 reagent was purchased from Proteintech (Wuhan,…

Continue Reading Taraxasterol suppresses the proliferation and tumor growth of androgen-independent prostate cancer cells through the FGFR2-PI3K/AKT signaling pathway

Research Trials

Condition: Solid Tumors Sponsor: Relay Therapeutics <b>Full Title</b><br> RLY-4008-101: A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors <br><br> <b>Study Treatment</b><br> Oral FGFR2 inhibitor RLY-4008 <br><br> <b>Eligibility/Info</b><br> Groups 1-5, 7: FGFR2-altered (fusion/mutation/amplification) solid tumor without…

Continue Reading Research Trials

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on track for 2H 2023 Enrollment for Phase 3 PEAK trial in GIST continues on track Selective FGFR2 inhibitor nominated as first Cogent-discovered clinical candidate; additional preclinical data planned…

Continue Reading Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Differential exon usage of developmental genes is associated with deregulated epigenetic marks

H3K36me3 mark is most relevant to AS events The first task was to prepare a suitable data set where differentially used exons (DEUs) can be clearly associated with individual genes. Hence, out of 19,240 clusters of protein coding genes generated for the DEXSeq analysis (see “Materials and methods” section), we…

Continue Reading Differential exon usage of developmental genes is associated with deregulated epigenetic marks

The combined action of the intracellular regions regulates FGFR2 kinase activity.

Receptor tyrosine kinases (RTKs) are typically activated through a precise sequence of intracellular phosphorylation events starting with a tyrosine residue on the activation loop (A-loop) of the kinase domain (KD). From this point the mono-phosphorylated enzyme is active, but subject to stringent regulatory mechanisms which can vary dramatically across the…

Continue Reading The combined action of the intracellular regions regulates FGFR2 kinase activity.

The combined action of the intracellular regions regulates FGFR2 kinase activity

To provide structure and clarity to the understanding of the intricate control mechanism herein investigated, we have deconstructed intracellular FGFR2 to the three principle regulatory regions: JM, KD and CT. This provides an understanding of how both JM and CT influence KD activation and dimerization. Through subsequent reconstruction of their…

Continue Reading The combined action of the intracellular regions regulates FGFR2 kinase activity

Exploring Co-Mutation Patterns Linked to Actionable Drivers in iCCA

The following is a summary of the “Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma,” published in the March 2023 issue of Hepatology by Kendre, et al. For precision oncology in gastrointestinal malignancies, intrahepatic cholangiocarcinoma (iCCA) has emerged as a “role model” in recent years. However, its genetic…

Continue Reading Exploring Co-Mutation Patterns Linked to Actionable Drivers in iCCA